Revenue segments as reported by the company.

Net product sales

Collaboration revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Other operating (income) expense, net

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Regeneron reports robust Q4 earnings, eyes strategic launches and collaborations

Regeneron Pharmaceuticals showcased strong financial performance and pipeline advancements in Q4 2022.
The company's focus on safety, efficacy, and strategic imperatives positions it for future growth.
Challenges include competitive positioning, trial data anticipation, and managing uncertainties.
Opportunities in market launches, accelerated approvals, and innovative collaborations drive future potential.

Regeneron excels in Q1 with strong revenue growth and pipeline advancements

Regeneron Pharmaceuticals delivered a strong performance in Q1 2023, driven by revenue growth and pipeline advancements in key therapeutic areas like DUPIXENT and EYLEA.
Despite operational challenges in market positioning and regulatory considerations, the company's strengths in research capabilities and strategic planning present growth opportunities.
With a focus on commercialization efforts, expanding indications, and leveraging genetic insights, Regeneron is poised to capitalize on opportunities for sustained success and innovation.
Navigating challenges in market competition and regulatory uncertainties, Regeneron remains proactive in addressing key issues to maintain its position as a leading biopharmaceutical company.

Regeneron reports strong Q2 earnings, eyes aflibercept launch

Regeneron Pharmaceuticals demonstrated strong financial performance and commercial success in Q2 2023.
While facing regulatory challenges, the company remains optimistic about pipeline advancements and potential launches.
Balancing efficacy and safety in treatments, Regeneron aims to capitalize on growth opportunities and strategic partnerships.
Robust cash position and focus on patient well-being position Regeneron for continued success and market expansion.

Regeneron posts robust Q3 results, eyes innovation and market growth

Regeneron's Q3 performance reflects strong revenue growth, financial stability, and promising market potential for key products like Dupixent and EYLEA HD.
While facing legal challenges and competitive pressures, the company's strategic focus on innovation, R&D, and shareholder value management positions it for long-term success.
With a robust pipeline, unique therapeutic targets, and a solid financial foundation, Regeneron is poised for continued growth, market leadership, and innovation in the biopharmaceutical industry.

Regeneron posts strong Q4 results, eyes growth through innovation

Regeneron Pharmaceuticals delivered a strong performance in Q4 2023, driven by successful product launches and financial results in line with expectations.
The company's focus on innovation, strategic leadership, and capital allocation priorities position them well for future growth and market success.
While facing challenges in market dynamics and competition, Regeneron has opportunities to leverage new product approvals and innovative treatment approaches.
Overall, Regeneron's performance highlights their resilience, strategic vision, and commitment to advancing healthcare through groundbreaking therapies.

Regeneron posts solid Q1 results, faces FDA request challenges

Regeneron Pharmaceuticals delivered strong financial performance in Q1 2024, driven by Dupixent and EYLEA HD.
The company's robust pipeline and focus on innovation position it well for future growth.
Challenges include FDA requests for Dupixent efficacy analyses and market entry hurdles for new products.
Opportunities lie in advancing therapies for COPD, severe food allergies, and expanding cancer treatment options.

Regeneron posts robust Q2 earnings, eyes pipeline expansion opportunities

Regeneron Pharmaceuticals demonstrated strong financial performance and product sales growth in Q2.
While facing regulatory challenges, the company's pipeline and market position remain robust.
Opportunities for expansion and innovation present avenues for future growth.
Overall, Regeneron's Q2 results reflect resilience and strategic focus.

Regeneron Pharmaceuticals reports strong Q3 results and eyes innovative growth

Regeneron's Q3 performance reflects solid revenue and earnings growth driven by key products. While facing regulatory challenges and capital allocation decisions, the company's focus on innovation and strategic investments positions it well for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron (REGN) obtains FDA approval for Praluent as an adjunct to diet and other LDL-C, lowering therapies to include pediatric patients aged eight and older with HeFH.

Regeneron (REGN) Gets FDA Nod for Praluent Label Extension

Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)

Approval extends treatment of Praluent to children aged 8 and older with heterozygous familial hypercholesterolemia (HeFH) Approval extends treatment of Praluent to children aged 8 and older with heterozygous familial hypercholesterolemia (HeFH)

Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol

Madrigal Pharmaceuticals

Vertex Pharmaceuticals

Madrigal Pharmaceuticals could be days away from winning its first FDA approval. Regeneron Pharmaceuticals expects several key regulatory decisions this year.

Missed Out on Eli Lilly? 3 Healthcare Stocks With Big Catalysts on the Horizon.

Exelixis

Regeneron boasts a pair of growth drivers that should still have plenty of fuel left. Exelixis is close to expanding its lineup with a promising late-stage candidate.

2 Biotech Stocks to Buy Hand Over Fist in March

Published results show EYLEA HD with extended 12- or 16-week dosing regimens demonstrated non-inferior vision gains to standard of care EYLEA ® (aflibercept) Injection 2 mg with fixed 8-week dosing in patients with wAMD and DME in the first year

EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) TD Cowen 44th Annual Health Care Conference March 6, 2024 11:10 AM ET Company Participants Marion McCourt - EVP of Commercial Ryan Crowe - SVP and Head of IR Conference Call Participants Tyler Van Buren - TD Cowen Tyler Van Buren All right. Good morning, everyone.

Regeneron Pharmaceuticals, Inc. (REGN) TD Cowen 44th Annual Health Care Conference Call Transcript

Biogen

If you're looking for biotech stocks to buy, the iShares Biotechnology ETF (NASDAQ: IBB ) is an excellent place to start. It tracks the performance of the ICE Biotechnology Index, a collection of U.S. companies in the biotech industry.

Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits

ATHENS, Greece--(BUSINESS WIRE)--GENESIS Pharma announces an exclusive distribution agreement with Regeneron Pharmaceuticals to commercialize cemiplimab in Greece, Cyprus and Malta.

GENESIS Pharma Announces an Exclusive Distribution Agreement With Regeneron Pharmaceuticals to Commercialize cemiplimab in Greece, Cyprus and Malta

Sanofi

Dupixent ® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation

Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation

Priority Review granted based on positive results from two Phase 3 trials; i f approved, Dupixent would be the only biologic therapy for COPD and the first new treatment approach for this disease in more than a decade

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation

Novo Nordisk

Novo Nordisk continues to innovate exactly where it counts. Regeneron's key growth drivers still have lots of room to run.

2 No-Brainer Biotech Stocks to Buy Right Now

TARRYTOWN, N.Y., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for linvoseltamab to treat adult patients with relapsed/refractory (R/R) multiple myeloma (MM) that has progressed after at least three prior therapies. The target action date for the FDA decision is August 22, 2024. Linvoseltamab is an investigational bispecific antibody designed to bridge B-cell maturation antigen on multiple myeloma cells with CD3-expressing T cells to facilitate T-cell activation and cancer-cell killing.

Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review

Companies combating life-altering diseases can be compelling long-term investments. Vertex just won an approval that could supercharge its growth in the next few years.

2 Top Growth Stocks to Buy With $1,000 Right Now

Japan first in the world to approve Dupixent ® for chronic spontaneous urticaria (CSU) Approval based primarily on results from Phase 3 trial showing Dupixent significantly reduced itch compared to placebo CSU is the fifth approved indication for Dupixent in Japan and the sixth indication for Dupixent globally Paris and Tarrytown, N.Y. February 16, 2024.

Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)

Approval based on results from Phase 3 trial showing Dupixent significantly reduced itch compared to placebo CSU is the fifth approved indication for Dupixent in Japan and the sixth indication for Dupixent globally TARRYTOWN, N.Y. and PARIS, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for Dupixent® (dupilumab) for the treatment of chronic spontaneous urticaria (CSU) in people aged 12 years and older whose disease is not adequately controlled with existing therapy.

Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)

Regeneron Pharmaceuticals, Inc. (REGN) Oppenheimer 34th Annual Healthcare Life Sciences Conference (Transcript)

Regeneron Pharmaceuticals reported strong Q4/2023 earnings, exceeding expectations and showing impressive growth from Dupixent and Libtayo. The company's next generation of blockbuster drugs are offsetting fading EYLEA sales, extending Regeneron's growth track into the next decade. Regeneron's big growth drivers are its Retinal franchise, Dupixent, and Libtayo, with potential supplementary drivers in immuno-oncology combinations and the obesity market.

Regeneron Pharmaceuticals: Time To Change My Strategy After Encouraging Q4 2024

Abbott Labs

Abbott Laboratories and Regeneron are looking to solve a problem Ozempic may exacerbate. Both could benefit from the substantial increase in popularity of meds like Ozempic as a result.

These 2 Stocks Are Trying to Ride the Ozempic Bandwagon: Are They Buys?

MercadoLibre

MercadoLibre's shares are trading at more than $1,000, while Regeneron's are getting close to that price. Neither company has ever conducted a stock split.

Stock-Split Watch: Could These 2 Market-Beaters Be Next?

Regeneron (REGN) beats earnings and sales estimates in fourth-quarter 2023, fueled by Dupixent. However, sales of the lead drug, Eylea, continue to fall.

Regeneron (REGN) Q4 Earnings & Sales Top, Eylea Sales Decline

Regeneron returned to topline growth in 2023 and this has led to the company's valuation rising to my expected EV/revenue range. The company is making significant investments in the obesity space, focusing on preserving lean mass and reducing fat mass. Q4 2023 earnings review shows further stabilization of the Eylea franchise, continued strong growth of Dupixent, and Libtayo, and we could see additional approvals this year.

Regeneron's Push Into Obesity, Q4 2023 Earnings Review

Regeneron Pharmaceuticals, Inc. (REGN) Q4 2023 Earnings Call Transcript

Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Regeneron (REGN) Reports Q4 Earnings: What Key Metrics Have to Say

Regeneron Pharmaceuticals put up a commanding fourth-quarter beat on Friday, helped by Praluent. REGN stock is trading at an all-time high.

News for Regeneron Pharmaceuticals Stock (REGN)